September 7 is World Duchenne Awareness Day. Today, we recognize the individuals living with Duchenne muscular dystrophy, as well as the families, caregivers, advocates, and researchers whose dedication strengthens this community every day. Living with Duchenne brings ongoing challenges that affect not only those diagnosed, but also the people who support them. We are continually inspired by the resilience of individuals and families navigating this journey, the advocates advancing awareness and access, and the researchers working to expand what may be possible for the future. This year marked an important milestone in Duchenne research: the first participant in the FUNCTION-DMD clinical trial received an investigational gene-editing treatment, PBGENE-DMD, designed to permanently address the underlying cause of his Duchenne muscular dystrophy. Progress like this is only possible because of the individuals and families who choose to participate in research and the clinical teams who partner with them every step of the way. At Precision BioSciences, we are grateful for the opportunity to learn from and work alongside the Duchenne community with the hope of making a meaningful difference for individuals and families affected by Duchenne. #WorldDuchenneDay #Duchenne #RareDisease

Precision BioSciences has commenced dosing in the Phase 1/2 FUNCTION‑DMD study, with the first patient receiving PBGENE‑DMD at Arkansas Children’s Hospital. This milestone marks the first clinical gene‑editing program for Duchenne muscular dystrophy and advances our wholly owned in vivo gene editing approach into the clinic. PBGENE‑DMD is designed to permanently edit a patient’s own dystrophin gene, with the aim of restoring production of a near full‑length, functional dystrophin protein. The study is enrolling ambulatory boys ages 2–7 with mutations between exons 45 and 55, a key hotspot region representing up to 60% of boys living with Duchenne. The Precision team is grateful to the patient, their family, and the clinical team for their commitment to advancing this important work. Initial safety data are expected by year-end 2026. Read the full release, loom.ly/QIQX9EA #PBGENEDMD #FUNCTIONDMD #Duchenne #DMD #GeneEditing #GeneTherapy #InVivoGeneEditing #ARCUS #RareDisease #ClinicalTrials

Precision BioSciences announced its second quarter 2026 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Read the full press release, loom.ly/MIhNNio #GeneEditing #Biotech $DTIL

How many of the 240 million people living with chronic hepatitis B worldwide will ever receive treatment or know they have it? On World Hepatitis Day, we’re reminded that hepatitis B remains a leading cause of liver cancer and liver‑related death globally, yet fewer than 5% of people living with chronic HBV are receiving treatment. Most remain undiagnosed and untreated. At Precision BioSciences, we are striving to advance PBGENE‑HBV, our wholly owned in vivo gene editing program being evaluated in the Phase 1 ELIMINATE‑B trial, and the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA. Elimination of cccDNA results in HBV viral cure because cccDNA is the only source of infectious replication (HBV DNA). On a day dedicated to hepatitis awareness, we pause to recognize the global burden of hepatitis B and the responsibility of working on approaches that aim to change what is possible for people living with this infection. For more information, visit loom.ly/sBJzafI #HepatitisB #HepatitisDay #HBV

Precision BioSciences has activated a second clinical site at Washington University School of Medicine in St. Louis for the Phase 1/2 FUNCTION‑DMD trial evaluating PBGENE‑DMD in boys ages 2-7 with Duchenne muscular dystrophy. This expansion marks another step toward assessing PBGENE‑DMD’s potential to restore near full‑length dystrophin and improve long‑term muscle function in patients with mutations between exons 45–55. Watch our latest DMD update: loom.ly/t3XCnQk #PBGENEDMD #FUNCTIONDMD #DMD #InVivoGeneEditing #ARCUS #PrecisionBioSciences

At the Jefferies Global Healthcare Conference in New York, the Precision BioSciences leadership team outlined how our proprietary ARCUS in vivo gene editing platform is advancing programs in chronic Hepatitis B and Duchenne muscular dystrophy. #PrecisionBioSciences #Jefferies $DTIL

"Being added to the Russell 2000 Index broadens our visibility with institutional investors at a pivotal time for Precision BioSciences," said Alex Kelly, Chief Financial Officer of Precision BioSciences. "We are advancing two wholly owned clinical programs, PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, with a cash runway supporting our operations through 2028." Read the full release here, loom.ly/Qxmv0lE #PrecisionBioSciences #Russell2000 $DTIL

Precision BioSciences was honored to join the CureDuchenne FUTURES National Conference in Orlando, participating on the Science Main Stage and in the exhibit hall. Gary Owens, Senior Director Gene Therapy / Program Lead, at Precision, presented in the Gene Therapy and Gene Editing session, and our team spent time at our booth listening, learning, and connecting with families and clinicians from across the Duchenne community. $DTIL #PrecisionBioScience #DMD

In case you missed the live event, here are a few of our favorite moments from Precision BioSciences’ recent virtual investor event on Duchenne Muscular Dystrophy (DMD)! Watch the full conversation to hear the Precision team and external experts discuss PBGENE‑DMD and the upcoming Phase 1/2 FUNCTION‑DMD clinical trial. Click here for the full replay, loom.ly/t3XCnQk

Precision BioSciences announced its first quarter 2026 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Read the full press release, loom.ly/PeFvD-E #GeneEditing #Biotech $DTIL

Nothing beats learning side‑by‑side with families. The Precision BioSciences team recently joined Jett Foundation’s Family Workshop in Salt Lake City, Utah, to listen, learn, and speak with families impacted by Duchenne muscular dystrophy. We appreciated the opportunity to share more about PBGENE‑DMD and to hear directly from caregivers and clinicians about what matters most as new treatment options move forward. Learn more about PBGENE-DMD and the Phase 1/2 FUNCTION-DMD study here, loom.ly/-wqqxIk

Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial application approval in two European countries. “Expanding ELIMINATE-B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE-HBV, the only gene editing therapy uniquely designed to eliminate cccDNA,” said Cindy Atwell, Chief Development and Business Officer of Precision BioSciences. “Given the strong investigator interest in PBGENE-HBV, especially following the late breaker oral presentation at The Liver Conference 2025, these new trial sites will build on our existing global clinical trial footprint as we advance PBGENE-HBV through the ELIMINATE-B trial.” To learn more, visit loom.ly/ore3n7A $DTIL

Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team presented new preclinical data on PBGENE‑DMD, the company’s in vivo gene editing candidate designed to restore near full‑length dystrophin and potentially benefit boys with mutations between exons 45–55. As Debra Miller of CureDuchenne noted, “IND clearance for PBGENE‑DMD is an exciting step forward, and we look forward to collaborating to help connect innovation with the patient families we serve.” Read the full release, loom.ly/-wqqxIk

Precision BioSciences announced its Q4 and fiscal year 2025 earnings and provided a business update! CFO, Alex Kelly, tells you what you need to know. Read the full press release, investor.precisionbioscience… #GeneEditing #Biotech $DTIL

Join Precision BioSciences for a virtual investor event on March 17 at 9 am ET! The event features key opinion leaders (KOL), Dr. Aravindhan Veerapandiyan, MD, Pediatric Neurologist and Associate Professor of Pediatrics, Arkansas Children’s Hospital, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy, who will join Precision leaders to discuss: - The unmet need for DMD patients - Current treatment landscape - PBGENE-DMD for Duchenne muscular dystrophy (DMD) and - An overview of the clinical trial design for the FUNCTION-DMD trial Register here: loom.ly/IWJYXbg Read the full PR: loom.ly/RX7H4kE $DTIL

From the podium to the photo wall, the Precision BioSciences team is making the most of TD Cowen’s 46th Annual Health Care Conference! Cassie Gorsuch, PhD, Chief Scientific Officer, Alex Kelly, Chief Financial Officer, and Naresh Tanna, Head of Investor Relations, highlighted the company's focused in vivo gene editing strategy and upcoming milestones for our wholly owned programs in chronic hepatitis B and Duchenne muscular dystrophy. Want to watch the presentation replay? Visit loom.ly/eyoTv2Y $DTIL

Precision BioSciences announced that it has earned a clinical development milestone payment of $7.5 million from TG Therapeutics for the ongoing development of azer-cel in multiple sclerosis. The payment was triggered as a result of progress in TG Therapeutics' Phase 1 study evaluating azer-cel in adults with relapsing forms of multiple sclerosis, which is being conducted under its license agreement with Precision. The milestone payment is expected to support Precision’s cash runway through 2028 and further advancement of the company’s wholly owned in vivo gene editing programs. Read the full release, loom.ly/ejTCLls

Precision BioSciences has received a U.S. FDA “Study May Proceed” notification for its investigational new drug (IND) application for PBGENE‑DMD, enabling initiation of clinical trial site activation for the Phase 1/2 FUNCTION‑DMD clinical study in patients with Duchenne muscular dystrophy (DMD). PBGENE‑DMD is Precision’s wholly owned, first‑in‑class in vivo gene editing investigational product designed to correct the underlying genetic cause of DMD through a novel one‑time gene editing therapy targeting mutations between exons 45 and 55, the “hot‑spot” region accounting for approximately 60% of boys with DMD. PBGENE‑DMD has been granted U.S. FDA Rare Pediatric Disease and Orphan Drug designations for the treatment of DMD. Read the full release, loom.ly/s6wbj-k

Celebrating 20 years of Precision! Last week, our team of “Precisioneers” came together to reflect on two decades of advancing gene-editing science and the progress we’re making toward new in vivo therapies for conditions such as chronic hepatitis B and Duchenne muscular dystrophy. As a clinical-stage gene editing company, we’re using our proprietary ARCUS platform to develop one-time, potentially durable treatments aimed at overcoming hard-to-treat genetic and infectious diseases. Here’s to our future of hope, and to the patients, partners, and colleagues who inspire us to keep pushing the science forward. $DTIL

Precision BioScience is proud to share new data at #AASLD2025 for PBGENE-HBV, our first-in-class gene editing therapy for chronic hepatitis B, presented by Man-Fung Yuen, MBBS, M.D., PhD, DSc, ELIMINATE-B Investigator, Chair Professor of The University of Hong Kong, and the Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital. These new late-breaking data represent a milestone for Precision BioSciences and for the entire field of chronic Hepatitis B because it is the first time clinicians have been able to target the root viral source of the disease. The safety data and tolerability profile, along with dose-dependent durable reductions in hepatitis B surface antigen and the first-ever liver biopsy data provide evidence that antiviral activity is being achieved through directly editing the viral genome in patients with chronic Hepatitis B. This further validates ARCUS as a differentiated platform with true curative potential. With no observed dose-limiting toxicities, we look forward to finishing dosing the third cohort to generate additional data for PBGENE-HBV in our pursuit of a cure that has been so elusive in the field of Hepatitis B drug development. Thank you to all of our investigators, collaborators, and patients who help drive this important progress. More updates to come as we push toward new standards of care for HBV. For more information, visit loom.ly/nrE9gr4 #GeneEditing #HBV #AASLD #Biotech #PrecisionBioSciences #DTIL